drugset / Trial / NCT00039325
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma
Phase 1/2
Completed
28 enrolled
Jonsson Comprehensive Cancer Center
National Institutes of Health (NIH) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Vaccines made by inserting a laboratory-treated gene into a person's white blood cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy and to see how well it works in treating patients with stage IV or recurrent malignant melanoma.
Timeline
- Start
- 2002-03
- Primary completion
- 2005-09
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dendritic cell-MART-1 peptide vaccine | Vaccine | 1e+06 cells | Other |
| Subject | dendritic cell-MART-1 peptide vaccine | Vaccine | 1e+07 cells | Other |